|Description||BC2059 is a novel β-catenin antagonist and its treatment dose-dependently induced apoptosis of cultured and primary AML BPCs. BC2059 also significantly improved the median survival of immune-depleted mice engrafted with either cultured or primary AML BPCs, showing nuclear expression of β-catenin.|
|Solubility||Soluble in DMSO, not in water|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
KY1220 is a novel inhibitor of the Wnt/ß-catenin pathway, destabilizing both β-catenin and Ras via targeting the Wnt/β-catenin pathway (IC50= 2.1 μM in HEK293 r...
KYA1797K is a potent, selective and dual inhibitor of Wnt/β-catenin (IC50= 0.75 µM) that significantly decreases reporter activities for the Wnt/β-catenin and M...
WAY-262611 is a wingless beta-Catenin agonist that increases bone formation rate.
BC2059 is a novel β-catenin antagonist and its treatment dose-dependently induced apoptosis of cultured and primary AML BPCs. BC2059 also significantly improved...